
|Articles|November 15, 2007
First-line treatment for neovascular AMD
Combination therapy using photodynamic therapy and verteporfin (Visudyne, Novartis) as well as bevacizumab (Avastin, Genentech) can be effective in patients with age-related macular degeneration (AMD), particularly when patients are naïve to treatment, according to results from a patient registry.
Advertisement
Advertisement
Latest CME
Advertisement
Advertisement
Trending on Ophthalmology Times - Clinical Insights for Eye Specialists
1
Oculis phase 3 DIAMOND trials miss vision endpoints in diabetic macular edema
2
The Residency Report: Cardiovascular risk scores as a window into ocular disease
3
TearSolutions advances Lacripep into phase 2 following dual FDA designations in neurotrophic keratitis
4
FDA guidance to help accelerate cell and gene therapies
5





















